Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis Stake Sale:...

    Fortis Stake Sale: Singh Brothers eye Rs 250 per share

    Written by savita thakur thakur Published On 2017-05-10T16:25:38+05:30  |  Updated On 10 May 2017 4:25 PM IST
    Fortis Stake Sale: Singh Brothers eye Rs 250 per share

    Mumbai: Following the development of two private equity funds giants -TPG Capital and General Atlantic Llc joining hands together in the race to acquire a controlling stake in Fortis healthcare, reports are now flowing in that the promoters of the Fortis Healthcare, Malvinder Singh and Shivinder Singh are looking at a valuation of Rs 250 per share. Currently, the shares are being traded at the NSE at around Rs 209.80 per share.


    Mint reports about the expected valuation adding that the deal may finalize in the coming few weeks. The main contender for the controlling share include TPG and General Atlantic alliance on one side and IHH healthcare on the other.


    Medical Dialogues team had earlier reported that 5 companies including KKR and Co. Lp ,Bain Capital, IHH along with TPG capital and General Atlantic had showed interest in Fortis Healthcare acquisition race. With two companies joining hands and two namely, KKR and Bain no longer showing interest, the battle for the stake sale boils down to two major contenders


    Read also: 5 Companies in the run to Aquire Fortis Healthcare


    After the stake sales, the Singh brothers who currently own a 67.5% stake in Fortis Healthcare will continue to be the single largest shareholders but will cede management control to the new investor, reports Mint.


    The deal is likely to be close in the next few weeks if the final round of negotiations conclude.


    “Both bidders have revised their bids and the discussions are in the range of Rs 250 per share for Fortis alone, and another Rs 2,000 crore for SRL,” said one of the sources informed the daily


    With a control premium, the deal could value Fortis at around Rs 12,000 crore. Moreover, SRL could be valued at Rs 4,500-5,000 crore, said the officials. The promoters are working towards demerger of SRL as well.


    Medical Dialogues had also reported that in order to reduce some of their debt burden, the Singh brothers earlier tried to sell some of the stake but Delhi High Court directed the two brother to seek the permission of the Delhi High Court before to sale of their assets. This was in light of the Daiichi appeal pending with the court, trying to prevent any sale by the brothers till the settlement of its Rs 2600 crore arbitration award.


    Read also: Do Not Sell any assets without Permission: Delhi HC to Singh Brothers


    Read also: Two Private Equity Giants join hands to take Over Fortis Healthcare, SRL


    AcquisitionBain CapitaldaiichiDelhi high courtFortisFortis HealthcareGeneral AtlanticIHHKKRMalvinder SinghMoney ValuationRHC Holding Pvt LtdShivinder SinghSRL DiagnosticsstakeTPG capital
    Source : with Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok